Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome

Summary

Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome (MONDO:0019375) is a disease with 3 cohort genes.

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Cohort genes: 3
• ClinVar variants: 339
• Phenotypes (HPO): 16

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		62	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

16 HPO clinical features (Orphanet curated; top 16 by frequency):

HPO ID	Term	Frequency
HP:0000238	Hydrocephalus	Very frequent (80-99%)
HP:0000256	Macrocephaly	Very frequent (80-99%)
HP:0001162	Postaxial hand polydactyly	Very frequent (80-99%)
HP:0001355	Megalencephaly	Very frequent (80-99%)
HP:0002126	Polymicrogyria	Very frequent (80-99%)
HP:0000160	Narrow mouth	Frequent (30-79%)
HP:0000316	Hypertelorism	Frequent (30-79%)
HP:0000348	High forehead	Frequent (30-79%)
HP:0000506	Telecanthus	Frequent (30-79%)
HP:0001250	Seizure	Frequent (30-79%)
HP:0001629	Ventricular septal defect	Frequent (30-79%)
HP:0001653	Mitral regurgitation	Frequent (30-79%)
HP:0001671	Abnormal cardiac septum morphology	Frequent (30-79%)
HP:0005105	Abnormal nasal morphology	Frequent (30-79%)
HP:0005280	Depressed nasal bridge	Frequent (30-79%)
HP:0100542	Abnormal localization of kidney	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome
Mondo ID	MONDO:0019375
OMIM	603387
Orphanet	83473
SNOMED CT	722036008
UMLS	C1863924
MedGen	355095
GARD	0010341
Is cancer (heuristic)	no

Also known as: megalencephaly and perisylvian polymicrogyria with postaxial polydactyly and hydrocephalus · megalencephaly, polymicrogyria, and hydrocephalus (MPPH) syndrome · megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome · MPPH syndrome

Data availability: 339 ClinVar variants · 3 GenCC gene-disease records · 6 cell lines.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › hydrocephalus › megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome

Related subtypes (6): obstructive hydrocephalus, communicating hydrocephalus, craniosynostosis-Dandy-Walker malformation-hydrocephalus syndrome, congenital hydrocephalus, baker Vinters syndrome, palmer pagon syndrome

Subtypes (3): megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

339 retrieved; paginated sample, class counts are floors:

158 likely benign, 101 uncertain significance, 50 benign, 17 conflicting classifications of pathogenicity, 12 benign/likely benign, 1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
39808	NM_005027.4(PIK3R2):c.1117G>A (p.Gly373Arg)	PIK3R2	Pathogenic	reviewed by expert panel
856239	NM_005027.4(PIK3R2):c.706G>A (p.Ala236Thr)	LOC130063979	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2109735	NM_005027.4(PIK3R2):c.1766A>G (p.Lys589Arg)	LOC130063980	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1190673	NM_005027.4(PIK3R2):c.734C>A (p.Ala245Asp)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1296705	NM_005027.4(PIK3R2):c.1243G>A (p.Ala415Thr)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1319057	NM_005027.4(PIK3R2):c.1217G>A (p.Arg406His)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1381828	NM_005027.4(PIK3R2):c.527G>A (p.Ser176Asn)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1392796	NM_005027.4(PIK3R2):c.271C>T (p.Arg91Trp)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1565321	NM_005027.4(PIK3R2):c.46C>T (p.Arg16Cys)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1600096	NM_005027.4(PIK3R2):c.2171C>T (p.Pro724Leu)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2077921	NM_005027.4(PIK3R2):c.1987G>C (p.Gly663Arg)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2086146	NM_005027.4(PIK3R2):c.827G>A (p.Ser276Asn)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2212053	NM_005027.4(PIK3R2):c.517G>A (p.Gly173Ser)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
2387831	NM_005027.4(PIK3R2):c.1522C>T (p.Arg508Cys)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
429932	NM_005027.4(PIK3R2):c.1694C>G (p.Pro565Arg)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
661297	NM_005027.4(PIK3R2):c.1076G>C (p.Ser359Thr)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
859412	NM_005027.4(PIK3R2):c.107C>T (p.Ala36Val)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
864121	NM_005027.4(PIK3R2):c.380T>C (p.Leu127Pro)	PIK3R2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1711475	NM_005027.4(PIK3R2):c.811G>T (p.Asp271Tyr)	LOC130063979	Uncertain significance	criteria provided, multiple submitters, no conflicts
1925630	NM_005027.4(PIK3R2):c.766_783dup (p.Pro261_Ser262insArgAlaProProProPro)	LOC130063979	Uncertain significance	criteria provided, single submitter
1954122	NM_005027.4(PIK3R2):c.595C>T (p.Arg199Trp)	LOC130063979	Uncertain significance	criteria provided, multiple submitters, no conflicts
2737997	NM_005027.4(PIK3R2):c.565G>A (p.Glu189Lys)	LOC130063979	Uncertain significance	criteria provided, single submitter
3698949	NM_005027.4(PIK3R2):c.560C>A (p.Thr187Asn)	LOC130063979	Uncertain significance	criteria provided, single submitter
3710461	NM_005027.4(PIK3R2):c.755C>A (p.Pro252Gln)	LOC130063979	Uncertain significance	criteria provided, single submitter
3718370	NM_005027.4(PIK3R2):c.655G>A (p.Ala219Thr)	LOC130063979	Uncertain significance	criteria provided, single submitter
3719478	NM_005027.4(PIK3R2):c.583C>T (p.Arg195Cys)	LOC130063979	Uncertain significance	criteria provided, single submitter
3725567	NM_005027.4(PIK3R2):c.576dup (p.Glu193fs)	LOC130063979	Uncertain significance	criteria provided, single submitter
4136879	NM_005027.4(PIK3R2):c.572C>T (p.Ser191Leu)	LOC130063979	Uncertain significance	criteria provided, multiple submitters, no conflicts
4751733	NM_005027.4(PIK3R2):c.700_701delinsCA (p.Ser234His)	LOC130063979	Uncertain significance	criteria provided, single submitter
536232	NM_005027.4(PIK3R2):c.721C>A (p.Pro241Thr)	LOC130063979	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 20 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
CCND2	Definitive	Autosomal dominant	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3	5
PIK3R2	Definitive	Autosomal dominant	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1	7
AKT3	Strong	Autosomal dominant	megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2	8

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
PIK3R2	Orphanet:83473	Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome
CCND2	Orphanet:83473	Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome
AKT3	Orphanet:83473	Megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome
AKT3	Orphanet:99802	Hemimegalencephaly

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
PIK3R2	HGNC:8980	ENSG00000105647	O00459	Phosphatidylinositol 3-kinase regulatory subunit beta	gencc,clinvar
CCND2	HGNC:1583	ENSG00000118971	P30279	G1/S-specific cyclin-D2	gencc
AKT3	HGNC:393	ENSG00000117020	Q9Y243	RAC-gamma serine/threonine-protein kinase	gencc

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
PIK3R2	Phosphatidylinositol 3-kinase regulatory subunit beta	Regulatory subunit of phosphoinositide-3-kinase (PI3K), a kinase that phosphorylates PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3).
CCND2	G1/S-specific cyclin-D2	Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition.
AKT3	RAC-gamma serine/threonine-protein kinase	AKT3 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	2	18.5×	0.008
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
PIK3R2	Kinase	yes	2.7.1.137	RhoGAP_dom, SH2, SH3_domain
CCND2	Other/Unknown	no		Cyclin_C-dom, Cyclin_N, Cyclin-like_dom
AKT3	Kinase	yes	2.7.11.1	Prot_kinase_dom, AGC-kinase_C, PH_domain

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cortical plate	2
ganglionic eminence	1
stromal cell of endometrium	1
adrenal tissue	1
cauda epididymis	1
seminal vesicle	1
calcaneal tendon	1
embryo	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
PIK3R2	138	ubiquitous	marker	cortical plate, ganglionic eminence, stromal cell of endometrium
CCND2	293	ubiquitous	marker	adrenal tissue, seminal vesicle, cauda epididymis
AKT3	231	ubiquitous	marker	cortical plate, calcaneal tendon, embryo

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CCND2	3,569
AKT3	3,392
PIK3R2	2,751

Intra-cohort edges

A	B	Sources
AKT3	PIK3R2	string_interaction

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PIK3R2	O00459	8
AKT3	Q9Y243	2
CCND2	P30279	1

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 136. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
CD28 dependent PI3K/Akt signaling	2	262.5×	0.003	PIK3R2, AKT3
Mitotic G1 phase and G1/S transition	2	122.8×	0.005	CCND2, AKT3
Extra-nuclear estrogen signaling	2	113.6×	0.005	PIK3R2, AKT3
VEGFA-VEGFR2 Pathway	2	92.8×	0.005	PIK3R2, AKT3
PIP3 activates AKT signaling	2	44.5×	0.018	PIK3R2, AKT3
AKT-mediated inactivation of FOXO1A	1	951.7×	0.019	AKT3
Inhibition of TSC complex formation by AKT (PKB)	1	761.3×	0.019	AKT3
Drug-mediated inhibition of CDK4/CDK6 activity	1	761.3×	0.019	CCND2
G-protein beta:gamma signalling	1	634.4×	0.019	AKT3
Signaling by LTK in cancer	1	543.8×	0.019	PIK3R2
RUNX2 regulates genes involved in cell migration	1	475.8×	0.019	AKT3
PI3K/AKT activation	1	423.0×	0.019	PIK3R2
AKT phosphorylates targets in the nucleus	1	380.7×	0.019	AKT3
IRS-mediated signalling	1	346.1×	0.019	PIK3R2
Co-stimulation by ICOS	1	346.1×	0.019	PIK3R2
Regulation of localization of FOXO transcription factors	1	317.2×	0.019	AKT3
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	1	292.8×	0.019	CCND2
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	1	292.8×	0.019	PIK3R2
Signaling by PDGFRA extracellular domain mutants	1	292.8×	0.019	PIK3R2
SARS-CoV-2 targets host intracellular signalling and regulatory pathways	1	292.8×	0.019	AKT3
Signaling by LTK	1	292.8×	0.019	PIK3R2
Downregulation of ERBB2:ERBB3 signaling	1	271.9×	0.019	AKT3
AKT phosphorylates targets in the cytosol	1	271.9×	0.019	AKT3
Regulation of TP53 Activity through Association with Co-factors	1	271.9×	0.019	AKT3
Activation of BAD and translocation to mitochondria	1	253.8×	0.019	AKT3
Regulation of beta-cell development	1	237.9×	0.019	AKT3
Regulation of RUNX1 Expression and Activity	1	223.9×	0.019	CCND2
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	1	211.5×	0.019	CCND2
Tie2 Signaling	1	200.3×	0.019	PIK3R2
Role of LAT2/NTAL/LAB on calcium mobilization	1	200.3×	0.019	PIK3R2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
insulin receptor signaling pathway	2	147.8×	0.002	PIK3R2, AKT3
positive regulation of artery morphogenesis	1	1123.5×	0.014	AKT3
cellular response to X-ray	1	561.7×	0.014	CCND2
negative regulation of PERK-mediated unfolded protein response	1	468.1×	0.014	AKT3
positive regulation of cell size	1	432.1×	0.014	AKT3
regulation of stress fiber assembly	1	330.4×	0.014	PIK3R2
regulation of mitochondrion organization	1	280.9×	0.014	AKT3
positive regulation of vascular endothelial cell proliferation	1	280.9×	0.014	AKT3
brain morphogenesis	1	244.2×	0.014	AKT3
positive regulation of cell migration involved in sprouting angiogenesis	1	244.2×	0.014	AKT3
regulation of protein localization to plasma membrane	1	216.1×	0.014	PIK3R2
negative regulation of cellular senescence	1	216.1×	0.014	AKT3
intracellular glucose homeostasis	1	193.7×	0.014	PIK3R2
regulation of actin filament polymerization	1	193.7×	0.014	PIK3R2
negative regulation of apoptotic process	2	23.2×	0.014	CCND2, AKT3
positive regulation of TOR signaling	1	165.2×	0.014	AKT3
homeostasis of number of cells within a tissue	1	147.8×	0.014	AKT3
long-term memory	1	140.4×	0.014	CCND2
positive regulation of protein import into nucleus	1	140.4×	0.014	PIK3R2
positive regulation of G1/S transition of mitotic cell cycle	1	133.8×	0.014	CCND2
positive regulation of blood vessel endothelial cell migration	1	130.6×	0.014	AKT3
T cell differentiation	1	127.7×	0.014	PIK3R2
adult locomotory behavior	1	100.3×	0.017	CCND2
negative regulation of MAPK cascade	1	100.3×	0.017	PIK3R2
positive regulation of cell adhesion	1	90.6×	0.018	PIK3R2
regulation of autophagy	1	80.2×	0.019	PIK3R2
positive regulation of endothelial cell proliferation	1	77.0×	0.019	AKT3
B cell differentiation	1	73.0×	0.019	PIK3R2
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1	70.2×	0.020	PIK3R2
G1/S transition of mitotic cell cycle	1	66.9×	0.020	CCND2

Therapeutics

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 0

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
PIK3R2	IDELALISIB
CCND2	PALBOCICLIB
AKT3	CAPIVASERTIB

Top cohort targets by molecule count

Symbol	Molecules	Max phase
AKT3	18	4
PIK3R2	6	4
CCND2	3	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
IDELALISIB	4	PIK3R2
INAVOLISIB	4	PIK3R2
PALBOCICLIB	4	CCND2
CAPIVASERTIB	4	AKT3
MIDOSTAURIN	4	AKT3
TASELISIB	3	PIK3R2
ALVOCIDIB	3	CCND2
IPATASERTIB	3	AKT3
AFURESERTIB	3	AKT3
ENZASTAURIN	3	AKT3
FASUDIL	3	AKT3
LESTAURTINIB	3	AKT3
RUBOXISTAURIN	3	AKT3
ROGINOLISIB	2	PIK3R2
AMDIZALISIB	2	PIK3R2
PICTILISIB	2	PIK3R2
MIRANSERTIB	2	AKT3
MK-2206	2	AKT3
UPROSERTIB	2	AKT3
BMS-387032	1	CCND2
AT-13148	1	AKT3
GSK-690693	1	AKT3
GSK-1070916	1	AKT3
JNJ-26483327	1	AKT3
PF-03758309	1	AKT3
BAY-1125976	1	AKT3
VEVORISERTIB	1	AKT3

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
AKT3	660	Binding:644, Functional:16
CCND2	28	Binding:28
PIK3R2	27	Binding:27

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PIK3R2	2.7.1.137	phosphatidylinositol 3-kinase
AKT3	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
AKT3	660

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

27 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
IDELALISIB	4	PIK3R2
INAVOLISIB	4	PIK3R2
PALBOCICLIB	4	CCND2
CAPIVASERTIB	4	AKT3
MIDOSTAURIN	4	AKT3
TASELISIB	3	PIK3R2
ALVOCIDIB	3	CCND2
IPATASERTIB	3	AKT3
AFURESERTIB	3	AKT3
ENZASTAURIN	3	AKT3
FASUDIL	3	AKT3
LESTAURTINIB	3	AKT3
RUBOXISTAURIN	3	AKT3
ROGINOLISIB	2	PIK3R2
AMDIZALISIB	2	PIK3R2
PICTILISIB	2	PIK3R2
MIRANSERTIB	2	AKT3
MK-2206	2	AKT3
UPROSERTIB	2	AKT3
BMS-387032	1	CCND2
AT-13148	1	AKT3
GSK-690693	1	AKT3
GSK-1070916	1	AKT3
JNJ-26483327	1	AKT3
PF-03758309	1	AKT3
BAY-1125976	1	AKT3
VEVORISERTIB	1	AKT3

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	PIK3R2, CCND2, AKT3
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.